[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Liquidia Corp (LQDA)

Liquidia Corp (LQDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,653,205
  • Shares Outstanding, K 89,509
  • Annual Sales, $ 158,320 K
  • Annual Income, $ -68,920 K
  • EBIT $ 169 M
  • EBITDA $ 170 M
  • 60-Month Beta 0.58
  • Price/Sales 43.93
  • Price/Cash Flow N/A
  • Price/Book 35.65

Options Overview Details

View History
  • Implied Volatility 106.44% (-0.39%)
  • Historical Volatility 72.83%
  • IV Percentile 39%
  • IV Rank 29.77%
  • IV High 185.25% on 10/31/25
  • IV Low 73.04% on 05/21/26
  • Expected Move (DTE 2) 4.27 (5.66%)
  • Put/Call Vol Ratio 0.52
  • Today's Volume 7,887
  • Volume Avg (30-Day) 14,396
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 216,952
  • Open Int (30-Day) 173,655
  • Expected Range 71.14 to 79.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.82
  • Number of Estimates 3
  • High Estimate $1.01
  • Low Estimate $0.66
  • Prior Year $-0.04
  • Growth Rate Est. (year over year) +2,150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.53 +6.29%
on 08/14/26
93.61 -18.78%
on 08/11/26
-3.91 (-4.89%)
since 07/17/26
3-Month
53.06 +43.29%
on 06/03/26
93.61 -18.78%
on 08/11/26
+16.05 (+26.76%)
since 05/19/26
52-Week
21.15 +259.56%
on 09/26/25
93.61 -18.78%
on 08/11/26
+48.92 (+180.45%)
since 08/19/25

Most Recent Stories

More News
Liquidia Corporation Reports Second Quarter 2026 Financial Results

YUTREPIA ® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient...

LQDA : 75.33 (+1.35%)
Liquidia's First Profitable Quarter: Is the Thesis Finally Working or Just Good Timing?

Barchart Research What to Expect from LQDA Earnings LQDA Generated August 11, 2026 Current Price $88.05 EPS Estimate $$0.70 Consensus Rating Strong Buy Average Move 6.55% Liquidia's First Profitable Quarter:...

LQDA : 75.33 (+1.35%)
This Little-Known Stock Has Surged 360% in the Past Year

Liquidia (LQDA) exhibits exceptional momentum with shares up more than 360% over the past 52 weeks. LQDA holds a 100% “Buy” technical opinion, with multiple analyst ratings supporting strong bullish...

LQDA : 75.33 (+1.35%)
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026

MORRISVILLE, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging...

LQDA : 75.33 (+1.35%)
Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions

MORRISVILLE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging...

LQDA : 75.33 (+1.35%)
Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

MORRISVILLE, N.C., June 08, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging...

LQDA : 75.33 (+1.35%)
Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

NEW YORK , June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading...

VIAV : 38.74 (-6.36%)
ROKU : 156.80 (-0.62%)
VITL : 10.87 (-1.27%)
LAZ : 45.21 (+2.61%)
CDE : 20.93 (+13.07%)
OXM : 35.49 (-0.28%)
IVT : 33.30 (-0.30%)
EBC : 23.01 (-2.54%)
PRAA : 19.44 (-1.07%)
CNXC : 25.72 (+8.66%)
EMBC : 5.42 (+6.27%)
CTKB : 4.70 (+0.64%)
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

MORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and...

LQDA : 75.33 (+1.35%)
Liquidia Q1 Earnings Call Highlights

Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and pulmonary...

LQDA : 75.33 (+1.35%)
Liquidia Corporation Reports First Quarter 2026 Financial Results

YUTREPIA ® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients...

LQDA : 75.33 (+1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Liquidia Corporation is a biopharmaceutical company. It develops, manufactures and commercializes products for unmet patient needs principally in the United States. Liquidia Corporation, formerly known as LIQUIDIA TECHNL, is based in Morrisville, North Carolina.

See More

Key Turning Points

3rd Resistance Point 80.40
2nd Resistance Point 78.58
1st Resistance Point 76.46
Last Price 75.33
1st Support Level 72.52
2nd Support Level 70.70
3rd Support Level 68.58

See More

52-Week High 93.61
Last Price 75.33
Fibonacci 61.8% 65.93
Fibonacci 50% 57.38
Fibonacci 38.2% 48.83
52-Week Low 21.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.